Pharmaceutical

AD/PD 2024: exploring cutting-edge therapies for ALS

While some biotechs are attempting to develop disease-modifying therapies for amyotrophic lateral sclerosis (ALS), it has proven challenging.

Mar 9, 2024 - 18:00
AD/PD 2024: exploring cutting-edge therapies for ALS
While some biotechs are attempting to develop disease-modifying therapies for amyotrophic lateral sclerosis (ALS), it has proven challenging.
Read the original article

Tags:

Previous Article

AD/PD 2024: TauRx’s HMTM promising despite lacking primary endpoint data

Next Article

FDA delays action on Lilly’s donanemab, intent on advisory committee meeting

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Listen: How the legal battle over abortion could thwart research, plus: the FDA ‘bully pulpit’ and Moderna’s future

Listen: How the legal battle over abortion could thwart...

Apr 13, 2023

Q3 2023 update: environmental sustainability related hi...

Oct 19, 2023

Shrinking Covid vaccine sales has Moderna course-correcting

Shrinking Covid vaccine sales has Moderna course-correc...

Nov 3, 2023